RxDoctor Payments Data

Mary Lee

Cardiovascular Disease · Temple, TXNPI 1831544642

Payments from drug & device makers

$1,975in general payments, 2019–2025

Across 67 payments — averaging $29.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$302
  • Novo Nordisk$255
  • Pfizer$187
  • Heartflow, Inc.$170
  • Cardiva Medical, Inc.$126
  • Johnson & Johnson$125
  • plus $811 from 14 others

What the payments were for

  • Food & beverage$1,975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,975 in reported general payments places this provider in the 35th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$154,662
Medicare patients
558
Services billed
1,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$113,398
MounjaroTirzepatide26$28,674
Repatha SureclickEvolocumab33$24,533
XareltoRivaroxaban19$17,366
JardianceEmpagliflozin13$9,566
BrilintaTicagrelor19$9,094
Varenicline Tartrate12$2,769
Clonidine25$2,708
Metoprolol Succinate134$1,680
Carvedilol163$1,182
Rosuvastatin Calcium112$1,021
Amlodipine Besylate145$865
Atorvastatin Calcium120$769
Potassium Chloride32$718
Losartan Potassium86$654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$113,398136 claims
Lilly USA, LLCMounjaro$37$28,67426 claims
Johnson & JohnsonXarelto$125$17,36619 claims
AstraZenecaBrilinta$70$9,09419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →